Key Conference Participation: MindMed CEO Rob Barrow will present at the J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, showcasing the company's advancements in psychiatry, which is expected to attract investor interest.
Clinical Trial Progress: The company plans to release three pivotal Phase 3 trial results in the upcoming year, targeting Generalized Anxiety Disorder and Major Depressive Disorder, potentially paving the way for future FDA submissions in these significant markets.
Investor Engagement Opportunity: This conference provides MindMed with a meaningful opportunity to engage with the investment community, aiming to enhance the company's visibility in the biopharmaceutical sector and attract potential investments.
Commitment to Innovation: MindMed is focused on developing innovative product candidates targeting neurotransmitter pathways to improve brain health, demonstrating the company's long-term strategic vision in the mental health treatment space.
MNMD
$12.54+Infinity%1D
Analyst Views on MNMD
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.130
Low
18.00
Averages
28.25
High
55.00
Current: 12.130
Low
18.00
Averages
28.25
High
55.00
Canaccord
Buy
upgrade
$16 -> $25
2025-11-07
Reason
Canaccord
Price Target
$16 -> $25
2025-11-07
upgrade
Buy
Reason
Canaccord raised the firm's price target on Mind Medicine to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug potential to its model and said the company is well capitalized and significantly undervalued heading into Phase 3 data.
LifeSci Capital
Francois Brisebois
Outperform
initiated
$32
2025-10-14
Reason
LifeSci Capital
Francois Brisebois
Price Target
$32
2025-10-14
initiated
Outperform
Reason
LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine with an Outperform rating and $32 price target.
Oppenheimer
Jay Olson
Outperform
initiated
$25
2025-08-04
Reason
Oppenheimer
Jay Olson
Price Target
$25
2025-08-04
initiated
Outperform
Reason
Oppenheimer analyst Jay Olson resumed coverage of Mind Medicine with an Outperform rating and $25 price target. The firm previously had no rating on the shares. The analyst has "high conviction" that the company's lead asset MM120 will "revolutionize" neuropsychiatry with its potential to drive durable remission. MM120 has a "unique" clinical profile with its less-intense but longer psychedelic experience compared to other approaches, the analyst tells investors in a research note.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$55
2025-03-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$55
2025-03-07
Reiterates
Strong Buy
Reason
About MNMD
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
